59,259 Shares in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Bought by GSA Capital Partners LLP

GSA Capital Partners LLP bought a new stake in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 59,259 shares of the company’s stock, valued at approximately $825,000. GSA Capital Partners LLP owned 0.06% of Day One Biopharmaceuticals at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Day One Biopharmaceuticals by 38.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,611 shares of the company’s stock valued at $51,000 after buying an additional 1,002 shares during the period. SG Americas Securities LLC purchased a new stake in Day One Biopharmaceuticals in the 2nd quarter worth approximately $113,000. Point72 DIFC Ltd acquired a new stake in shares of Day One Biopharmaceuticals during the 2nd quarter worth approximately $124,000. Hsbc Holdings PLC purchased a new position in shares of Day One Biopharmaceuticals during the 2nd quarter valued at approximately $163,000. Finally, SteelPeak Wealth LLC acquired a new position in shares of Day One Biopharmaceuticals in the 2nd quarter valued at $218,000. 87.95% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently commented on DAWN. Bank of America upgraded shares of Day One Biopharmaceuticals from an “underperform” rating to a “buy” rating and raised their price target for the company from $11.00 to $24.00 in a research report on Thursday, August 1st. JPMorgan Chase & Co. dropped their target price on shares of Day One Biopharmaceuticals from $38.00 to $36.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 6th. Wedbush restated an “outperform” rating and set a $33.00 price target on shares of Day One Biopharmaceuticals in a research report on Thursday, July 25th. HC Wainwright reiterated a “buy” rating and issued a $40.00 price objective on shares of Day One Biopharmaceuticals in a report on Thursday, October 31st. Finally, Needham & Company LLC reissued a “buy” rating and set a $33.00 target price on shares of Day One Biopharmaceuticals in a report on Thursday, October 31st. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Buy” and an average price target of $35.71.

Insiders Place Their Bets

In other news, insider Samuel C. Blackman sold 30,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $14.22, for a total transaction of $426,600.00. Following the completion of the sale, the insider now owns 1,097,535 shares in the company, valued at $15,606,947.70. This trade represents a 2.66 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold 51,745 shares of company stock valued at $775,867 over the last ninety days. Company insiders own 8.40% of the company’s stock.

Day One Biopharmaceuticals Price Performance

DAWN opened at $13.31 on Friday. Day One Biopharmaceuticals, Inc. has a 1-year low of $11.30 and a 1-year high of $18.07. The firm has a market capitalization of $1.34 billion, a price-to-earnings ratio of -12.92 and a beta of -1.51. The company’s 50 day simple moving average is $14.42 and its two-hundred day simple moving average is $14.37.

Day One Biopharmaceuticals (NASDAQ:DAWN) last issued its earnings results on Wednesday, October 30th. The company reported $0.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.58. The company had revenue of $93.76 million during the quarter, compared to analyst estimates of $15.05 million. During the same period last year, the business earned ($0.54) earnings per share. On average, equities analysts anticipate that Day One Biopharmaceuticals, Inc. will post -0.88 earnings per share for the current fiscal year.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.